Less than 10% of people who could benefit from GLP-1 drugs like Wegovy are able to get them, caution the global health agency as it issues its initial guidance on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging increased and just availability to this class of drugs.
According to forecasts, more than two billion will be obese by 2030 without intervention.
"Our latest guidelines affirms that obesity is a long-term condition that can be addressed with holistic and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key obstacles to universal availability to the injections that can help people shift significant weight, explains the body.
Skinny Jab Scarcity
Even in the current most favorable scenario, the manufacturing of these medications could only cover around 100 million people – under 10% of eligible patients, per the health organization.
The recommendation encourages countries and companies to widen access, by approaches like patent sharing.
Exclusive production rights on a key compound – the core ingredient of the drug Wegovy – is due to expire in multiple nations in 2026.
How Weight-Loss Drugs Work
These medications imitate a natural hormone to delay gastric emptying, curb appetite and boost the sense of being full so people reduce food intake.
Individuals usually start to lose weight within a few weeks of beginning the weekly injections.
Evidence points to people may see weight return a year later of discontinuing the medication, when their usual appetite come back.
Being overweight or obese raises your likelihood for contracting health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity impacts individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.
